Healthy volunteers test new drug for rare lung and liver disease
NCT ID NCT06186492
First seen Mar 23, 2026 · Last updated May 19, 2026 · Updated 9 times
Summary
This study tested a new drug called WVE-006 in 47 healthy volunteers to see if it is safe and how the body processes it. The goal was to gather information for future trials in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs and liver. Participants received either a single dose or multiple doses of the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Simbec-Orion Clinical Pharmacology,
Merthyr Tydfil, Wales, CF48 4DR, United Kingdom
Conditions
Explore the condition pages connected to this study.